Want to see JP:4524 full AI Analyst Report?
4524 Stock Chart & Stats
¥2187.00
¥4.00(0.19%)
At close: 4:00 PM EST
¥2187.00
¥4.00(0.19%)
Day’s Range― - ―
52-Week Range¥2,100.00 - ¥2,390.00
Previous CloseN/A
Volume1.20K
Average Volume (3M)1.68K
Market Cap
¥8.86B
Enterprise Value¥8.74B
Total Cash (Recent Filing)¥1.83B
Total Debt (Recent Filing)¥1.76B
Price to Earnings (P/E)14.2
Beta0.32
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.55%
Share Statistics
EPS (TTM)153.31
Shares Outstanding4,150,000
10 Day Avg. Volume1,530
30 Day Avg. Volume1,680
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)0.70
Price to Sales (P/S)0.72
P/FCF Ratio506.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA strong equity base and historically low leverage provide a durable financial cushion against shocks and fund strategic choices. This conservatism supports dividend payments, withstands temporary cash gaps, and preserves the company's ability to invest selectively without forcing distressed financing.
Established Domestic Brand And DistributionWell-known flagship brands and entrenched retail channels create sustained demand and shelf presence in Japan's consumer healthcare market. Brand recognition and established distribution reduce customer acquisition costs and support steady retail sell-through, underpinning predictable revenue streams over time.
Improving Operating Cash GenerationA meaningful rebound in operating cash flow indicates the core business can generate cash when operations improve, enhancing liquidity for working capital, modest capex, and dividends. Sustained OCF strength would reduce reliance on external funding and improve financial flexibility.
Bears Say
Volatile Free Cash FlowIrregular free cash flow undermines the company's ability to fund discretionary activities like product development, marketing, or M&A without tapping reserves or increasing debt. Persistent FCF volatility raises execution risk and constrains long-term strategic investments and payout consistency.
Top-line Softness In 2026A decline in revenue after prior growth suggests demand weakening or product cycle drag in core OTC categories. Prolonged top-line stagnation limits operating leverage benefits, pressures margins over time, and forces management to find structural growth avenues or accept slower earnings progression.
Rising Debt LevelAn increase in total debt, even from a low base, raises fixed obligations and reduces balance sheet optionality. If cash generation remains uneven, higher leverage could constrain investment choices, limit defensive flexibility in downturns, and require tighter capital allocation discipline going forward.
4524 FAQ
What was Morishita Jintan Co., Ltd.’s price range in the past 12 months?
Morishita Jintan Co., Ltd. lowest stock price was ¥2100.00 and its highest was ¥2390.00 in the past 12 months.
What is Morishita Jintan Co., Ltd.’s market cap?
Morishita Jintan Co., Ltd.’s market cap is ¥8.86B.
When is Morishita Jintan Co., Ltd.’s upcoming earnings report date?
Morishita Jintan Co., Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 20 days.
How were Morishita Jintan Co., Ltd.’s earnings last quarter?
Morishita Jintan Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥64.89 earnings per share for the quarter, beating the consensus estimate of N/A by ¥64.89.
Is Morishita Jintan Co., Ltd. overvalued?
According to Wall Street analysts Morishita Jintan Co., Ltd.’s price is currently Overvalued.
Does Morishita Jintan Co., Ltd. pay dividends?
Morishita Jintan Co., Ltd. pays a Annually dividend of ¥65 which represents an annual dividend yield of 2.55%. See more information on Morishita Jintan Co., Ltd. dividends here
What is Morishita Jintan Co., Ltd.’s EPS estimate?
Morishita Jintan Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Morishita Jintan Co., Ltd. have?
Morishita Jintan Co., Ltd. has 4,150,000 shares outstanding.
What happened to Morishita Jintan Co., Ltd.’s price movement after its last earnings report?
Morishita Jintan Co., Ltd. reported an EPS of ¥64.89 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.825%.
Which hedge fund is a major shareholder of Morishita Jintan Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4524
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Morishita Jintan Co., Ltd.
Morishita Jintan Co., Ltd. is a Japanese enterprise that manufactures and distributes a diverse array of products, encompassing pharmaceuticals, quasi-pharmaceuticals, medical devices, and food items. The company's operations are divided into two main segments: Healthcare Business and Capsule Business. The Healthcare Business division is responsible for the production and sale of its proprietary Jintan branded goods, and also provides original equipment manufacturing (OEM) services for dietary supplements, cosmetic products, and various food items. Concurrently, the Capsule Business division handles both original equipment and design manufacturing (OEM/ODM) for pharmaceutical and food sectors, in addition to innovating and developing capsules for industrial applications. Established in 1893, the company's headquarters are located in Osaka, Japan.
Technical Analysis
―
Tsumura & Co
―
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―